RESUMEN
Objective To investigate the remission rate of the therapy of integrated TCM into intensive insulin treatment, and the relationship between each factor and the remission rate. The effect of TCM on improving ?-cell fimction and remission rate was also studied. Methods Forty-seven newly diagnosed type 2 diabetic patients were shortly treated with both continuous subcutaneous insulin infusion (CSII) and Chinese medicine. The remission rate was observed. The relationship between each factor and remission was analyzed by logistic regression. The ?-cell function of patients in remission group were evluated at the end of the treatment and during the period of follow-up. Results After treatment of (11.8?2.5)d, BMI and the ratio of the days of blood glucose reaching the standard and the total treatment days were the mainly factors affecting the remission. The remission rate at the end of treatment, one month after treatment and follow-up period (about six month) was 46.8%, 55.3%, 53.3% respectively. In following up, the remission rate in the Chinese medicine group and the control group was 66.7%, 44.4% respectively. Conclusions About half of newly diagnosed type 2 diabetic patients obtain clinical remission after the short-term intensive treatment of integrated insulin and Chinese medicine. Chinese medicine may have positive impaction on remission and extending honeymoon period.
RESUMEN
PURPOSE: Type I diabetes mellitus(DM) is an autoimmune disease which decreases insulin secretion of pancreatic beta-cell. The honeymoon period in type I DM is known to be related to the partial recovery of C-peptide and preservation of pancreatic beta-cell function. The aim of this study was to determine factors influencing the onset of honeyrnoon period in children with type I DM. METHODS: The study group was composed of 50 patients with type I DM. The honeymoon period was defined as a period requiring less than 0.5U/kg/day to maintain near-normal blood glucose control without urine glucose for consecutive days. The factors for three study were age at diagnosis, sex, initial 24-hr urine C-peptide, initial HbA C, diabetic ketoacidosis and maximum insulin dose for near-normal blood glucose control before honeymoon. RESULTS: The group with honeymoon period received significantly smaller doses of insulin near-normal blood glucose control, compared to the group without honeymoon period, before honeymoon(P<0.01). Other factors had no significant connection with the development of honeymoon period. CONCLUSION: The developrnent of honeymoon period in type I DM had a significant relationship with maximum insulin dose before the onset of honeymoon period for near-normal blood glucose control. This needs remains to be further study.